Oral cancer is characterized by its insidious onset, difficult diagnosis, and rapid progression and is often accompanied by metastasis and disabling treatment. The high mortality and morbidity rates associated with the disease highlight the need for an effective screening method and the development of early diagnostic tools. Currently, routine oral examination (visual and tactile inspection of accessible oral structures), together with tissue biopsy, remains the gold standard for diagnosing potentially malignant diseases (PMDs) and oral squamous cell carcinoma (OSCC). However, this method also possesses certain limitations, such as sampling bias, which can result in underdiagnosis or misdiagnosis, especially for multifocal lesions. Therefore, there is an urgent need to explore noninvasive, rapid, and economical screening methods with high enough sensitivity and specificity for the early diagnosis of oral cancer.
Highlights of the webinar:
Oral cancer is one of the most common head and neck malignancies and has an overall 5-year survival rate that remains below 50%.
Oral cancer is generally preceded by oral potentially malignant disorders (OPMDs) but determining the risk of OPMD progressing to cancer remains a difficult task.
Several diagnostic technologies have been developed to facilitate the detection of OPMD and oral cancer, and some of these have been translated into regulatory-approved in vitro diagnostic systems or medical devices.
To date, a visual oral examination remains the routine first-line method of identifying oral lesions; however, this method has certain limitations and as a result, patients are either diagnosed when their cancer reaches a severe stage or a high-risk patient with OPMD is misdiagnosed and left untreated.
The purpose of this webinar is to review the currently available diagnostic methods for oral cancer as well as possible future applications of novel promising technologies to oral cancer diagnosis.
Date :02/06/2024 | 11:00 AM
